JP2012518420A5 - - Google Patents

Download PDF

Info

Publication number
JP2012518420A5
JP2012518420A5 JP2011551315A JP2011551315A JP2012518420A5 JP 2012518420 A5 JP2012518420 A5 JP 2012518420A5 JP 2011551315 A JP2011551315 A JP 2011551315A JP 2011551315 A JP2011551315 A JP 2011551315A JP 2012518420 A5 JP2012518420 A5 JP 2012518420A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
residue
polypeptide
recombinant polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011551315A
Other languages
English (en)
Japanese (ja)
Other versions
JP5841845B2 (ja
JP2012518420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/025260 external-priority patent/WO2010099219A2/en
Publication of JP2012518420A publication Critical patent/JP2012518420A/ja
Publication of JP2012518420A5 publication Critical patent/JP2012518420A5/ja
Application granted granted Critical
Publication of JP5841845B2 publication Critical patent/JP5841845B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011551315A 2009-02-24 2010-02-24 TGF−βスーパーファミリーのデザイナーリガンド Active JP5841845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15506609P 2009-02-24 2009-02-24
US61/155,066 2009-02-24
PCT/US2010/025260 WO2010099219A2 (en) 2009-02-24 2010-02-24 Designer ligands of tgf-beta superfamily

Publications (3)

Publication Number Publication Date
JP2012518420A JP2012518420A (ja) 2012-08-16
JP2012518420A5 true JP2012518420A5 (https=) 2013-04-04
JP5841845B2 JP5841845B2 (ja) 2016-01-13

Family

ID=42666199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011551315A Active JP5841845B2 (ja) 2009-02-24 2010-02-24 TGF−βスーパーファミリーのデザイナーリガンド

Country Status (6)

Country Link
US (2) US8952130B2 (https=)
EP (1) EP2401293B1 (https=)
JP (1) JP5841845B2 (https=)
KR (1) KR101558642B1 (https=)
CA (1) CA2752647A1 (https=)
WO (1) WO2010099219A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
JP6254146B2 (ja) * 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
WO2015070076A2 (en) * 2013-11-08 2015-05-14 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
JP7065610B6 (ja) * 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
US10130678B2 (en) 2014-12-29 2018-11-20 Bioventus, LLC. Systems and methods for improved delivery of osteoinductive molecules in bone repair
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドScholar Rock,Inc. Gdf11結合タンパク質およびその使用
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
WO2017209519A1 (en) 2016-05-31 2017-12-07 Mogam Institute For Biomedical Research Ab6 family designer ligands of tgf-beta superfamily
KR20190005240A (ko) * 2016-05-31 2019-01-15 재단법인 목암생명과학연구소 Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용
KR20190005239A (ko) * 2016-05-31 2019-01-15 재단법인 목암생명과학연구소 Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 간질환 치료용 조성물 및 그의 이용
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
CA3044371C (en) 2016-12-30 2024-01-16 Biogend Therapeutics Co., Ltd. Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
US11261225B2 (en) 2017-02-10 2022-03-01 Institute For Cancer Research Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance
CN118255902A (zh) 2017-03-02 2024-06-28 加拿大国家研究委员会 TGF-β受体胞外域融合分子及其用途
WO2020101366A1 (en) * 2018-11-15 2020-05-22 joint Center for Biosciences Activin/bmp7 chimeras: super-active sab704 and sab715, and their respective noggin-sensitized variants, nab704 and nab715; and nab204
CN114728072A (zh) 2019-10-23 2022-07-08 库尔生物制药有限公司 TGF-β多肽
CA3174130A1 (en) * 2020-11-23 2022-05-27 Cue Biopharma, Inc. Tgf-beta polypeptides
KR20240150761A (ko) 2022-01-28 2024-10-16 35파마 인크. 액티빈 수용체 유형 iib 변이체 및 이의 용도
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5106748A (en) * 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5108922A (en) * 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US4877864A (en) * 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
ZA874681B (en) * 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5155058A (en) * 1986-11-07 1992-10-13 Canon Kabushiki Kaisha Method of making semiconductor memory device
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1991005802A1 (en) 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
WO1992007004A1 (en) 1990-10-18 1992-04-30 Creative Biomolecules, Inc. Osteogenic protein
US5677196A (en) * 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US6333168B1 (en) * 1993-05-20 2001-12-25 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of dorsalin-1
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
ATE417927T1 (de) 1997-07-30 2009-01-15 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US6846906B1 (en) * 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
WO2006047728A2 (en) * 2004-10-27 2006-05-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Bmp gene and fusion protein

Similar Documents

Publication Publication Date Title
JP2012518420A5 (https=)
JP2018138049A5 (https=)
BRPI0513143A (pt) antagonistas de vla-4 multivalentes compreendendo porções poliméricas
JP2008508859A5 (https=)
JP2012507271A5 (https=)
RU2506274C2 (ru) Способы скрининга с применением g-белок сопряженных рецепторов и родственных композиций
JP2019530463A5 (https=)
JP2010166916A5 (https=)
JP2010519293A5 (https=)
JP2010519931A5 (https=)
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2013107899A5 (https=)
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2010519252A5 (https=)
WO2009103105A3 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
JP2015134796A5 (https=)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2011507903A5 (https=)
JP2012188436A5 (https=)
JP2018508530A5 (https=)
JPWO2019156137A5 (https=)
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
JP2012505657A5 (https=)
MX2008009493A (es) Peptido novedoso y uso del mismo.